Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1374652-22-8 | MDL No. : | MFCD22380551 |
Formula : | C3H10Cl2N2O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | VCIUOQVHKQLWNE-UHFFFAOYSA-N |
M.W : | 161.03 | Pubchem ID : | 92132824 |
Synonyms : |
|
Num. heavy atoms : | 8 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 1.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 34.95 |
TPSA : | 47.28 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -7.04 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 0.34 |
Log Po/w (WLOGP) : | 0.45 |
Log Po/w (MLOGP) : | -0.23 |
Log Po/w (SILICOS-IT) : | -0.41 |
Consensus Log Po/w : | 0.03 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -0.99 |
Solubility : | 16.6 mg/ml ; 0.103 mol/l |
Class : | Very soluble |
Log S (Ali) : | -0.9 |
Solubility : | 20.4 mg/ml ; 0.127 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | 0.19 |
Solubility : | 249.0 mg/ml ; 1.55 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.56 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
2.88 mmol | With hydrogenchloride In 1,4-dioxane; methanol at 20℃; for 5h; | 66 Oxetan-3-ylhydrazine hydrochloride General procedure: To a solution of Boc-protected hydrazine (1 .0 eq.) in MeOH (0.5 M) was added 4 N HCI in 1 ,4-dioxane (8.0 eq.) and the reaction was stirred at RT for 5 h. Diethyl ether was added and a precipitate formed which was collected by filtration to provide the desired hydrazine intermediate. Alternatively, the mixture was concentrated under reduced pressure and used as such.; Following general procedure G, tert-butyl N-(oxetan-3-ylamino)carbamate (3.84 mmol) gave the titledcompound (2.88 mmol) as a brown oil. 1H NMR (400 MHz, DMSO-d6, ): 3.81-3.71 (m, 2H), 3.61 -3.53(m, 2H), 3.25-3.19 (m, 1H) |
[ 936249-35-3 ]
(2-Methoxyethyl)hydrazine hydrochloride
Similarity: 0.77
[ 885330-03-0 ]
(2-Methoxyethyl)hydrazine dihydrochloride
Similarity: 0.77
[ N/A ]
(2-Methoxyethyl)hydrazine hydrochloride hydrate
Similarity: 0.77
[ 1384427-89-7 ]
2-Hydrazinylpropan-1-ol dihydrochloride
Similarity: 0.82
[ 936249-35-3 ]
(2-Methoxyethyl)hydrazine hydrochloride
Similarity: 0.77
[ 885330-03-0 ]
(2-Methoxyethyl)hydrazine dihydrochloride
Similarity: 0.77
[ N/A ]
(2-Methoxyethyl)hydrazine hydrochloride hydrate
Similarity: 0.77